The SNF3 gene is required for high-affinity glucose transport in the yeast Saccharomyces cerevisiae and has also been implicated in control of gene expression by glucose repression. We report here the nucleotide sequence of the cloned SNF3 gene. The predicted amino acid sequence shows that SNF3 encodes a 97-kilodalton protein that is homologous to mammalian glucose transporters and has 12 putative membrane-spanning regions. We also show that a functional SNF3-lacZ gene-fusion product cofractionates with membrane proteins and is localized to the cell surface, as judged by indirect immunofluorescence microscopy. Expression of the fusion protein is regulated by glucose repression.
Transport of glucose in the yeast Saccharomyces cerevisiae, as in most mammalian cell types, occurs by carrier-mediated facilitated diffusion (1) (2) (3) . Bisson and Fraenkel (4, 5) showed by kinetic analysis of glucose uptake that yeast has a constitutive low-affinity transport system (Km 20 mM for glucose) and a glucose-repressible high-afflinity system (Km 1 mnM). Previously, Neigeborn and Carlson (6) described the isolation of mutations in the SNF3 (sucrose nonfermenting) gene that caused defects in regulation of glucose-repressible genes, and Neigeborn et al. (7) reported the cloning of SNF3 and the construction of snJ3 null mutations. Mutations in SNF3 cause defects in growth on glucose at low concentration (0.1%) and on sugars such as sucrose, which is hydrolyzed extracellularly by invertase to yield glucose and fructose. Subsequent studies showed that snJ3 mutants lack the high-affinity glucose-uptake system, whereas lowaffinity uptake appears to be unimpaired (8) . These findings suggested the possibility that SNF3 encodes a structural component of the high-affinity glucose-uptake system. We therefore determined the sequence of the cloned SNF3
gene,t and we report here that SNF3 encodes a protein that is homologous to mammalian glucose transporters. We also show that a functional SNF3-lacZ gene-fusion product cofractionates with membrane proteins and is localized to the cell surface. Expression of the gene fusion is regulated by glucose repression.
MATERIALS AND METHODS Nucleotide Sequence Analysis. Intact and BAL-31 nuclease-treated restriction fragments from the SNF3 gene were cloned in the vectors M13mpl8 and M13mpl9 (9) . The sequence of both strands was determined by the method of Sanger et al. (10) with the 17-nucleotide sequencing primer (Amersham).
Computer Methods. Amino acid sequences were aligned with the assistance of the program ALIGN (30) .
Construction of SNF3-lacZ Fusions. SNP'3-lacZ gene fusions were constructed by inserting SNF3 DNA fragments containing at least 0.8 kilobases of 5' noncoding sequence into the 2-Am plasmid vectors YEp353 and YEp357R (11) .
The SNF3(3)-lacZ fusion was constructed by inserting an EcoRI-BamHI fragment into YEp353, SNF3(321)-lacZ by inserting a Sal I-Spe I fragment into YEp357R, and SNF3-(797)-lacZ by inserting a Sal I-EcoRI fragment into YEp-357R.
Preparation of Glucose-Derepressed Cells. Wild-type (SNF3) yeast cells carrying each of the SNF3-lacZ gene fusions were grown to midlogarithmic phase in synthetic complete medium containing 2% glucose, with selection for the plasmid. Cells were derepressed by shifting to medium containing 0.05% glucose for 3 hr.
Protein Fractionation and Enzyme Assays. Crude lysates were prepared from glucose-derepressed cells as described (12) , except that protease inhibitor was omitted, and were fractionated by centrifugation at 13,000 x g in a microcentrifuge (Fisher) at 4°C. Protein concentrations were determined with the Bio-Rad protein-assay kit. p-Galactosidase (13), dipeptidyl aminopeptidase (14) , and glucose-6-phosphate dehydrogenase (15) were assayed as described.
Indirect Immunofluorescence. Cells were fixed with formaldehyde, treated with Glusulase (DuPont) and Zymolyase lOOT (Seikagaku Kogyo, Tokyo), immobilized on polylysine-coated slides, and stained with antibody and 4',6-diamidino-2-phenylindole (DAPI), essentially as described (16) 
RESULTS
Sequence Homology Between the SNF3-Encoded Protein and Mammalian Glucose Transporters. We determined the nucleotide sequence of a 3690-base-pair region of the previously cloned (7) SNF3 gene. Fig. 1 shows the nucleotide sequence and the inferred amino acid sequence. The sequence of the predicted 96,713-dalton protein (884 amino acids) was compared to the sequences of the glucose transporters from human HepG2 hepatoma cells (17) and rat brain (18 
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Sequence homology of the predicted SNF3 protein, human HepG2 glucose transporter (HGT) (17) , and E. coli xylose-H + (XyJE) and arabinose-H + (AraE) transporters (19) . Sequences (given in standard single-letter amino acid symbols) were aligned to maximize identity to the SNF3 sequence. Dashes indicate gaps introduced to optimize the alignment. Identities with the SNF3 protein are boxed. Putative transmembrane regions in the SNF3 and HepG2 transporters are shaded. Amino acids are numbered on the left.
The hydrophobicity profile suggests that the SNF3 protein contains 12 membrane-spanning regions (Fig. 3) , as has been found for the mammalian and E. coli transporters. The spacing of the putative membrane-spanning regions (shaded in Figs. 1 and 2 ) is similar for the yeast and mammalian glucose transporters, suggesting a similar structure. The membrane-spanning regions are arranged in two groups of six, separated by a region that is rich in charged residues (22 of 70 and 25 of 65 residues are charged for the SNF3 and HepG2 transporters, respectively). In several cases, uncharged polar residues within predicted membrane-spanning regions are conserved between the SNF3 and HepG2 proteins-for example, the glutamine and asparagine residues in hydrophobic regions 7 and 11, respectively. Mueckler et al. (17) suggested that these residues may be involved in forming amphipathic a-helices that might function in a glucose binding site or pore. The most striking difference between the SNF3 protein and the mammalian glucose transporters is that the former is much larger, with an additional 85 amino acids at the amino terminus and 303 amino acids at the carboxyl terminus. We did not detect homology between these terminal regions and the proteins in the Protein Identification Resource of the National Biomedical Research Foundation. for the mammalian transporters, the SNF3 protein has no apparent signal sequence adjacent to the amino terminus. Two lines of evidence indicate that the carboxyl-terminal 87 amino acids are not required for SNF3 function: both the EcoRI fragment ending at codon 797 (7, 8) and a gene fusion between SNF3 and the E. coli lacZ gene at this site produce a functional transporter and complement an snJ3 null mutation (see below). An interesting feature of the carboxylterminal region is a sequence of 23 amino acids that occurs at two positions (680 and 776) with 17 of 23 residues identical (underlined in Fig. 1) .
Another difference between the SNF3 and HepG2 transporters is that the N-linked glycosylation site assigned to Asn-45 of the human glucose transporter (17, 22) (20) with the normalized consensus hydrophobicity values of Eisenberg (21) hydrophobic regions and, moreover, complements an snJ3 null mutation. The SNF3(321)-1acZ fusion protein might also be expected to cofractionate with membrane proteins, since it contains the first 6 hydrophobic regions; Mueckler and Lodish (22) showed that the first 8 membrane-spanning regions of the HepG2 glucose transporter allow insertion into microsomes in vitro. The SNF3(3)-lacZ fusion protein, however, should remain soluble.
To test these predictions, crude protein lysates prepared from cells carrying each of the three gene fusions were fractionated by centrifugation at 13,000 x g, and the supernatant and pellet fractions were assayed for f3-galactosidase, glucose-6-phosphate dehydrogenase, and the membraneassociated enzyme dipeptidyl aminopeptidase. The Xgalactosidase activity associated with the SNF3(797)-lacZ and SNF3(321)-lacZ fusion proteins cofractionated with dipeptidyl aminopeptidase (Table 1) , whereas the control (Fig. 4a) . The control, the SNF3(3)-lacZ gene product, was distributed throughout the cytoplasm but was excluded from the vacuole (data not shown). Interestingly, the SNF3(321)-lacZ protein was not localized to the plasma membrane but rather was found in a cap-like structure around the nucleus (Fig. 4 b and c) . This finding suggests that the first six membrane-spanning regions are not sufficient for correct localization; however, we cannot exclude the possibility that the presence of the p-galactosidase moiety at this position interferes in some way.
Regulation of SNF3-lacZ Fusion Protein by Glucose Repression. We next examined the regulation of the SNF3(797)-lacZ fusion protein by glucose repression. Previous studies showed that expression of the SNF3 RNA is about 5-fold glucose-repressible (7) and that high-affinity glucose transport is glucose-repressible (5 (25, 26) .
DISCUSSION
Three lines of evidence argue strongly that SNF3 encodes a glucose transporter: previous genetic evidence that SNF3 is required for high-affinity glucose transport (7, 8) ; the sequence homology between the SNF3 protein and mammalian glucose transporters; and the localization of a functional SNF3-lacZ fusion protein to the plasma membrane. In addition to its transport function, the SNF3 protein may also be involved in regulatory mechanisms for monitoring the availability of glucose; certain snJ3 missense mutations cause defects in repression and derepression of glucoserepressible genes (6, 7) . The SNF3 protein is not, however, absolutely essential for regulation, since glucose repression is normal in an snf3 null mutant (7) . It is noteworthy that the dependence of high-affinity glucose transport on the presence of hexose kinases (2) (3) (4) suggests interaction between the SNF3 protein and kinases. Hexokinase P11 (B) has been implicated in control of glucose repression (27) (28) (29) ; thus, the regulatory effects of the SNF3 protein might be mediated by interaction with hexokinase PII.
Mutational analysis of the structure and function of this glucose transporter by use of the cloned SNF3 gene will be facilitated by the availability of snj3 null mutants of yeast. Moreover, proteins that are functionally related to the SNF3-encoded transporter, including those that interact physically, can be identified by isolating extragenic suppressor mutations that restore function in an snJ3 missense or null mutant. Genetic analysis should also yield insight into the regulation of SNF3 expression in response to glucose availability.
